JCN Newswire
TOKYO and CAMBRIDGE, Mass., Aug 22, 2024 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc.announced today that the humanized amyloid-beta(Aβ) monoclonal antibody “Leqembi®” (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain.1 Lecanemab is indicated for the treatmentof mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein Eε4 (ApoE ε4)* heterozygotes or non-carriers.1 Lecanemab becomes the first treatment for early AD (MCI and mild dementia due to AD)2 that targets an underlying cause of the disease…
Read More
Leqembi (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain
Stephania Pekar
07:47
TOKYO and CAMBRIDGE, Mass., Aug 22, 2024 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc.announced today that the humanized amyloid-beta(Aβ) monoclonal antibody “Leqembi®” (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain.1 Lecanemab is indicated for the treatmentof mild cognitive
